MindMed completes 50% subject enrolment and dosing in GAD therapy trial

Mind Medicine (MindMed) has enrolled and dosed more than 50% participants in its Phase IIb trial of MM-120 (lysergide D-tartrate) to treat generalised anxiety disorder (GAD).